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In recent years, regulatory T  cells (Treg)-based immunotherapy has emerged as a 
promising strategy to promote operational tolerance after solid organ transplantation 
(SOT). However, a main hurdle for the therapeutic use of Treg in transplantation is 
their low frequency, particularly in non-lymphopenic hosts. We aimed to expand Treg 
directly in vivo and determine their efficacy in promoting donor-specific tolerance, using 
a stringent experimental model. Administration of the IL-2/JES6-1 immune complex 
at the time of transplantation resulted in significant expansion of donor-specific Treg, 
which suppressed alloreactive T  cells. IL-2-mediated Treg expansion in combination 
with short-term CD154–CD40 co-stimulation blockade, but not CTLA-4 Ig or rapamy-
cin, led to tolerance to MHC-mismatched skin grafts in non-lymphopenic mice, mainly 
by hindering alloreactive CD8+ effector T  cells and the production of alloantibodies. 
Importantly, this treatment also allowed prolonged survival of allografts in the presence 
of either donor-specific or cross-reactive memory cells. However, late rejection occurred 
in sensitized hosts, partly mediated by activated B cells. Overall, these data illustrate 
the potential but also some important limitations of Treg-based therapy in clinical SOT 
as well as the importance of concomitant immunomodulatory strategies in particular in 
sensitized hosts.
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inTrODUcTiOn
Current immunosuppressive (IS) protocols are efficient in protecting against acute allograft rejec-
tion. However, the chronic administration of IS drugs is associated with toxicities and is often insuf-
ficient in preventing chronic allograft dysfunction, therefore hindering optimal patient and graft 
long-term outcome (1, 2). Due to their pleiotropic immune regulatory functions, the therapeutic 
potential of antigen-specific CD4+Foxp3+ regulatory T cells (Treg) has been highlighted in autoim-
mune diseases as well as in allogeneic hematopoietic stem cell and solid organ transplantation (SOT) 
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(3–6). We and others have described targeted therapies based on 
ex vivo expansion of antigen-specific Treg that can, upon adop-
tive transfer into the recipient, control alloreactive effector T cells 
(Teff) and prevent acute and chronic allograft rejection (5, 7, 8). 
The constitutive low frequencies of thymic-derived Treg (tTreg) 
requires expansion of tTreg or induction of Treg from naïve 
conventional CD4+ T  cells to achieve high Treg:Teff ratios for 
therapeutic efficacy after SOT, in particular in non-lymphopenic 
hosts (9–11). However, immunotherapeutic strategies based on 
ex vivo Treg production are challenging as they require highly 
selective purification and expansion methods in GMP facilities. 
Antigen-specificity is another issue implying the availability of 
donor-derived cells, as well as the in vivo stability and suppressive 
capacity of Treg after transfer (12–16).
An alternative approach would be the expansion of Treg 
directly in vivo in the presence of defined alloantigens. It has been 
shown that IL-2 signaling through the high-affinity IL-2R consti-
tutively expressed on tTreg is essential for their homeostasis and 
IS function through the level of Foxp3 and CD25 expression (17). 
The clinical benefit of utilizing IL-2 to enhance Treg numbers has 
been reported in two recent publications (18, 19). However, a 
major problem with the therapeutic use of many cytokines is their 
short half-life in the circulation following administration (20). 
Furthermore, high-dose IL-2 may activate other cells expressing 
the IL-2R, such as memory CD8+ T cells and NK cells. Boyman 
et  al. first described the use of an IL-2/JES6-1 complex (IL2c) 
that not only had a longer half-life than IL-2 alone but also could 
selectively expand Treg in vivo by sterically blocking IL-2/IL-2Rβ 
and IL-2/IL-2Rγ interactions and increasing the affinity of IL-2 
to IL-2Rαhigh Treg (21, 22). Additionally, treatment with a similar 
IL2c has been recently shown to increase the stability of Foxp3 
expression (15).
In this study, we aimed to expand Treg directly in  vivo 
using an IL2c and determine their suppressive function and 
efficacy in promoting donor-specific tolerance in a stringent 
MHC-mismatched skin transplantation (Tx) model. Since we 
predicted that the expansion of the Treg pool alone would not 
be sufficient to prevent rejection in non-lymphophenic hosts, 
we explored how IL2c treatment could be best combined with 
immunomodulatory drugs to control alloreactive T and B cells, in 
naïve as well as in pre-sensitized hosts. Our data demonstrate that 
IL2c administration combined with CD154–CD40, but not with 
CD28-B7 co-stimulation blockade or rapamycin (Rapa), could 
induce allograft tolerance in non-lymphopenic naive recipients. 
However, tolerance was not achieved in pre-sensitized hosts (har-
boring allospecific or cross-reactive memory), as late rejection 
occurred, partly mediated by activated B cells.
MaTerials anD MeThODs
Mice
Wild-type C57BL/6 (B6, H2b), BALB/c (H2d), CBA (H2k), and 
B6xDBA2 F1 (B6D2, H2bxH2d) mice were purchased from 
Charles-River and Elevage Janvier. Unless specified, all experi-
mental procedures were performed on 8- to 12-week-old sex- and 
age-matched female mice. All mice were maintained in the 
specific pathogen-free animal facilities of the CHUV.
In Vivo expansion of Treg
IL-2/anti-IL-2 complexes (IL2c) were prepared as previously 
described (21). In brief, 0.05  mg/kg recombinant mouse IL-2 
was mixed with 0.25  mg/kg anti-IL-2 (clone JES6-1) and 
incubated at 37°C for 30 min. Mice were injected i.p. for three 
consecutive days.
T-cell Purification
Single-cell suspensions were obtained by passing spleens and 
lymph nodes (LN) through 70-µm cell-strainers. After erythro-
cytes lysis, cells were incubated with the following rat anti-mouse 
hybridoma culture supernatants: anti-MHCII (M5/114, TIB-
120/ATCC; Manassas, VA, USA), anti-CD45R/B220 (RA3-3A1, 
TIB-146/ATCC), and anti-CD16/32 (2.4G2, HB-197/ATCC) 
followed by sheep anti-rat DynaBeads® (Invitrogen) before 
separation in a magnetic field. CD4+ T  cells were negatively 
selected using in addition anti-CD8 (YTS169; Therapeutic 
Immunology Group, Oxford, UK) in the purification cocktail. 
CD4+CD25− and CD4+CD25+ subsets were selected using 
anti-CD25-biotinylated (clone 7D4; BD Biosciences) followed 
by Streptavidin-MicroBeads® (MiltenyiBiotec, Germany), as 
described (5).
generation of Dendritic cells (Dc)
Fresh bone marrow cells flushed from femurs and tibias were 
passed through 70-µm cell-strainers. After erythrocytes lysis, 
BM cells were incubated with supernatants from YTS169, YTS191 
(anti-CD4; Therapeutic Immunology Group, Oxford, UK), 
M5/114, and RA3-3A1, followed by sheep anti-rat Dynabeads®. 
After magnetic separation, cells were transferred to 24-well plates 
in the presence of 20  ng/ml mouse recombinant granulocyte/
macrophage colony-stimulating factor (GM-CSF; R&D Systems). 
On days 2 and 4, medium containing small non-adherent cells was 
removed and replaced with fresh GM-CSF-containing medium. 
For maturation, 1 µg/ml LPS (E. coli 026:B6, Sigma) was added 
on day 6 for the final 12 h.
cell cultures
Cell cultures were performed in RPMI-1640 (Sigma) sup-
plemented with 100  IU/ml penicillin, 100  µg/ml streptomycin, 
2mM l-glutamine, 0.01  M Hepes, 50  µM 2β-mercaptoethanol 
(Invitrogen), and 10% heat-inactivated fetal calf serum (FCS) 
(EuroClone, UK), incubated at 37°C in a humidified atmosphere 
with 5% CO2. Proliferation assays were performed in triplicates 
in 96-well plates. T cells (1 × 105 cells/well) were stimulated with 
anti-CD3/CD28-coated beads (Dynabeads® Mouse T-Activator; 
Invitrogen) at a 1:1 bead:cell ratio for 3 days. Alternatively, a mixed 
lymphocyte reaction (MLR) was performed for 6 days, using a 
1:5 allogeneic DC:T ratio. For suppression assays, CD4+CD25− 
(Tconv) were cultured alone or cocultured with CD4+CD25+ 
(Treg) T cells (1:1, 2:1, and 4:1 ratios) in the presence of allogeneic 
DC or polyclonal stimulation. Cell proliferation was measured by 
[3H]-thymidine incorporation (cpm) at 72 h of culture or by flow 
cytometry analysis of CFSE dilutions of labeled Tconv. The equa-
tion: [(cpm of Tconv alone − cpm of Tconv cultured with Treg)/
(cpm of Tconv alone) × 100] was used to calculate the percentage 
of suppression.
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skin Transplantation and In Vivo 
Treatments
All surgical procedures were performed under general anesthesia 
(xylazine/ketamine) and no pain-control medication was added 
afterward. Full-thickness tail skins from donors were grafted on 
beds prepared on the lateral flanks of female B6 recipients. Graft 
sites were protected under sterile gauze and a plaster, removed at 
day 10. Grafts were observed daily afterward and were considered 
rejected when no viable skin remained. Mice were injected i.p. 
with 10  mg/kg cyclosporine A (CsA) (Sandimmun, Novartis 
Pharma Schweiz) from day 0 to 10; 25 mg/kg anti-CD40L (anti-
CD154, clone MR1; BioXcell, West Lebanon, NH, USA) on 
days 0, 2, and 4; 12.5 mg/kg CTLA-4 Ig on days 0, 2, 4, and 6 
(Belatacept; Bristol-Myers Squibb); 10 mg/kg anti-LFA-1 (anti-
M17/4, BioXcell) on days 0, 2, and 4; or received 1 mg/kg Rapa 
(Rapamune; Pfizer AG) by oral gavage from day 1 to 10 post Tx. 
In some experiments, 3 mg/kg Rapa (Calbiochem) was given i.p. 
from day 0 to 5. To obtain immunization, recipient female B6 
mice were injected s.cut with 5 ×  105 DC from B6D2 or male 
B6 donors, or 0.5  mg/kg of azide/endotoxin-free anti-CD3 
(145-2C11 eBioscience) 8–10 weeks prior to Tx.
antibodies and Flow cytometry
The following anti-mouse fluorochrome-conjugated mAbs and 
their respective isotype controls were used: CD3 (145-2C11), 
CD4 (clone RM4-5), CD8 (53-6.7), CD44 (IM7), CD49d (DX5), 
CD62L (MEL-14), B220 (RA3-6B2), IL-2 (JES6-5H4), IFN-γ 
(XMG1.2), IL-10 (JES5-16E3), IL-17 (TC11-18H10), MHC class 
II (I-A/I-E), PD-1 (CD279), all purchased from BD Biosciences; 
Helios (22F6) from Biolegend; and CD25 (PC61) and Foxp3 
(FJK-16s) from eBioscience. For the detection of cytokines, 
cells from spleen and LN were resuspended at approximately 
4 × 106 cells/ml in RPMI-10% FCS, restimulated with 50 ng/ml 
phorbol 12-myristate 13-acetate (PMA) and 0.5 µg/ml ionomycin 
for 5 h, in the presence of 10 µg/ml Brefeldin A (Sigma). Cells 
were then harvested, surface stained, fixed for 10  min in BD 
FACS Lysing Solution (BD Biosciences), and washed and per-
meabilized with PermBuffer (eBioscience) before intracellular 
staining. Intracellular Foxp3 staining was performed using a 
Foxp3 staining kit (eBioscience). The staining of antigen-specific 
CD4+ T  cells was carried out using the MHC class II I-Ab 
HY (116-130) NAGFNSNRANSSRSS tetramer (TCMetrix, 
Epalinges, Switzerland). Flow cytometry acquisition was done on 
FACS-Calibur™ using CellQuest™ (BectonDickinson) and data 
analyzed using FlowJo 9.5.3 software (Treestar).
histology
Skin grafts were fixed in 4% buffered formalin and embedded 
in paraffin. Sections (6 µm) were stained with H&E, according 
to standard protocols. For immunohistochemistry, sections 
were baked at 55°C for 20 min, cooled, deparaffinized, and rehy-
drated through graded alcohols to water. For antigen retrieval, 
slides were placed in pre-heated (95–100°C) Tris–EDTA buffer 
(10 mM Tris base, 1 mM EDTA, 0.025% Tween 20, pH 9.0) and 
microwaved for 20′ at 240 W. Endogenous peroxidase and biotin 
were blocked by 10′ incubation in 3% hydrogen-peroxide and 
Biotin Blocking System (Dako), respectively. After 30′ blocking 
in PBS-4% BSA-0.05% Tween 20, the slides were incubated with 
biotinylated anti-Foxp3 (clone FJK-16S, eBioscience), followed 
by Streptavidin/HRP (Dako). Slides were washed, incubated 
with liquid diaminobenzidine-tetrahydrochloride plus substrate 
(DakoCytomation) for 15′, rinsed with water, and counterstained 
with hematoxylin. All images were captured with a Nikon Eclipse 
E800 microscope and digital DXM1200 camera.
Detection of Donor-specific igg
Serum was collected from control non-transplanted, rejecting, 
and tolerant (day 100 post Tx) B6 recipient mice at the time of 
sacrifice and heat inactivated at 56°C for 30  min. Thymocytes 
from donor (B6D2), syngeneic, and third party (CBA) strains 
were collected and passed through 70-µm cell-strainers to obtain 
single-cell suspensions. Heat-inactivated non-diluted serum was 
incubated with 1 × 106 thymocytes at 37°C for 30 min. The bind-
ing of serum IgG to thymocytes was detected by flow cytometry 
using fluorochrome-conjugated polyclonal anti-IgG (Poly4060; 
Biolegend). A negative control of B6D2 thymocytes stained 
with IgG without prior incubation with serum was included. 
Alloantibody levels were quantified by analyzing the mean fluo-
rescence intensity (MFI) of bound IgG Abs.
statistical analysis
All experiments were repeated at least twice. Unpaired two-tailed 
Students t-test (comparison between two groups) and one-way 
ANOVA with Tukey’s post-test for multiple comparisons were 
used to calculate significance levels between treatment groups 
(GraphPad Prism version 6, CA, USA). Graft survival (median 
survival time, MST) was analyzed by Kaplan–Meier curves and 
the log-rank test. P values <0.05 were considered significant 
(*P < 0.05, **P < 0.01, and ***P < 0.001).
resUlTs
The il-2/Jes6-1 complex (il2c) expands 
Functional Treg In Vivo
We first addressed how we could best take advantage of directly 
expanding Treg in  vivo and, therefore, determined kinetics of 
immune cell-subsets following IL2c administration in the blood 
on days 3, 5, 7, and 10 after treatment as compared to PBS-treated 
controls (Figure S1 in Supplementary Material). In the absence 
of immune activation, we observed a selective and significant 
increase in CD4+CD25+CD44+Foxp3+ T  cells frequencies and 
numbers (3.3 vs.14.9% and 18 vs. 82 cells/100 µl blood; in PBS 
and IL2c groups, respectively), that peaked on day 5, persisted 
until day 7, and returned to baseline by day 10 (Figure S1A–G 
in Supplementary Material). At day 10, further analysis of the 
immune cell subsets in peripheral lymphoid organs showed 
that, in the absence of immune activation, higher frequencies of 
CD4+Foxp3+ T cells only persisted in the spleen (Figure S1H–N 
in Supplementary Material).
We next investigated whether these in  vivo-expanded Treg 
retained their phenotype and suppressive function. BALB/c mice 
were treated with either IL2c or control PBS for three consecutive 
FigUre 1 | Phenotype and suppressive function of regulatory T cells expanded in vivo with il2c. BALB/c mice received IL2c (open bars) or PBS (solid bars) 
treatment i.p. on days 0, 1, and 2. On day 5, spleen and peripheral axillary and inguinal lymph nodes (LN) were harvested. (a) Peripheral LN and spleen in PBS and 
IL2c-treated mice. (B) Total number of CD4+ T cells in pooled spleen and LN after T-cell purification. (c) Ratio of CD25+/CD25− within purified CD4+ T cells.  
(D) Representative plots and summary data of LN cells for the expression of Foxp3, CD25, Ki67, Helios, CTLA-4, and PD-1 (gated on CD4+ or CD4+Foxp3+).  
(e) CD4+CD25− T cells (1 × 105) were cultured alone or cocultured with CD4+CD25+ T cells (cell ratios of 1:1, 2:1, or 4:1) and anti-CD3/CD28 beads. Alternatively,  
(F) CD25− subset isolated from PBS-treated cultured with CD25+ from PBS or IL2c-treated mice; or (g) CD25− from IL2c-treated with CD25+ from PBS or IL2c-treated 
mice; in the presence of anti-CD3/CD28 beads. All conditions were plated in triplicates and the data are representative of three independent experiments. Dot-plots 
show the percentage of subsets within regions/quadrants, bar graphs represent mean ± SEM. n = 3–4 mice/group (*P < 0.05, **P < 0.01, and ***P < 0.001).
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days, followed by harvest of spleen and peripheral axillary and 
inguinal LN on day 5 (corresponding to the peak rate of expansion) 
for cell counts and characterization. Enlarged lymphoid organs 
and increased total cell counts were observed in IL2c as compared 
to PBS-treated mice, with a sevenfold higher CD25+/CD25− ratio 
within the CD4+ population in treated mice (Figures 1A–C). We 
confirmed a selective expansion of CD4+CD25+Foxp3+ T cells by 
day 5 of IL2c treatment, as determined by Ki67 expression by flow 
cytometry (Figure 1D). Foxp3+ T cells from control PBS-treated 
mice or after in vivo expansion had a similar expression of Helios, 
suggesting preferential expansion of tTreg rather than peripheral 
induction of Treg upon IL2c treatment in steady-state condi-
tions (23). Additionally, the surface expression of the inhibitory 
molecules PD-1 and CTLA-4 was significantly increased in IL2c-
expanded Treg. To determine the suppressive function of IL2c-
expanded Treg, CD4+CD25+ (Treg) and CD4+CD25− (Tconv) 
T-cell subsets were purified from both groups for in vitro cocul-
tures. While IL2c-expanded Treg suppressed the proliferation 
of Tconv in a dose-dependent manner in response to polyclonal 
activation, they tended to be less suppressive than control Treg 
on a cell-per-cell basis (Figures  1E–G). However, control Treg 
(purified from PBS-treated mice) could similarly suppress Tconv 
from both groups, ruling out increased responsiveness of Tconv 
after in vivo exposure to IL2c. Overall, these results demonstrated 
that treatment with the IL2c selectively expanded functional Treg 
in vivo.
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il2c-expanded Treg Promote Prolonged 
survival of Mhc-Mismatched skin 
allografts
We reasoned that with the in vivo expansion of Treg at the time of 
Tx, the strong alloreactive T-cell pool could be controlled, result-
ing in prolonged allograft survival. Wild-type non-lymphopenic 
C57BL/6 (B6) recipient mice were grafted with B6xDBA2 F1 
(B6D2) donors skins and either received no drugs (controls), 
intraperitoneal injection (i.p.) of IL2c starting the day prior to 
Tx, or other known IS drugs. Recipients treated with either CsA 
or Rapa rejected their allografts in a similar tempo as compared 
to the control non-treated group (MST =  15, 16, and 14  days; 
in CsA, Rapa, and control groups, respectively). Treatment with 
either IL2c or anti-CD154 mAb (MR1) alone resulted in signifi-
cant prolongation of graft survival in this MHC-mismatched skin 
Tx setting (MST = 24, ***P < 0.0001 and 22 days, ***P < 0.0001, 
respectively) (Figure 2A).
Cell suspensions were prepared from spleen and graft draining 
LN (dLN) of recipient mice at rejection to analyze alloreactive 
T-cell responses (dLN data only shown). As compared to con-
trols and CsA-treated mice, Rapa, MR1, and IL2c treatments 
resulted in significant higher frequencies of CD4+Foxp3+ 
T cells, with IL2c-treated mice displaying the highest numbers 
(Figures  2B–E). All treatments resulted in lower CD4+ and 
CD8+ T-cell activation as judged by the surface expression of 
CD25 and CD44 (Figures 2F,G). Interestingly, the LN homing 
receptor L-selectin (CD62L) remained significantly upregulated 
on CD4+ and CD8+ T cells after IL2c treatment (Figure 2H), sug-
gesting that this treatment and/or the presence of expanded Treg 
prevented effector/memory differentiation. No differences in the 
frequency of B220+ B cells were observed among groups in the 
graft dLN at rejection (Figure 2I). Finally, in contrast to mice that 
rejected their allograft at an earlier time-point, MR1 and IL2c-
treated mice had significantly lower frequencies of CD4+IFN-γ+, 
CD8+IFN-γ+, CD4+IL-2+, as well as CD4+IL-17+ Teff, however 
without favoring IL-10-producing CD4+ T cells (Figures 2J–M). 
Overall, IL2c treatment allowed the expansion of the Treg pool 
even after Tx and immune activation, which may have to some 
extent controlled the activation and proliferation of CD4+ and 
CD8+ Teff in response to the allograft, resulting in prolonged graft 
survival.
il2c combined with anti-cD154 Promotes 
Mhc-Mismatched skin graft Tolerance in 
immunocompetent Mice
Increasing the number of Treg at the time of Tx proved insuf-
ficient to promote graft tolerance, suggesting that additional 
immunomodulatory therapies would be necessary to regulate 
the strong early direct pathway alloresponse in our model. 
Therefore, we investigated whether Rapa or MR1 had an effect on 
the in vivo expansion of Treg when administered in combination 
with IL2c in steady-state conditions, i.e., in the absence of an 
immune response. We chose not to use CsA in further experiments 
as by inhibiting TCR downstream calcineurin-dependent signal-
ing, therefore IL-2 production, CsA was shown to compromise 
Treg homeostasis and function (24). As compared to PBS-treated 
mice, there was an enlargement of the LN and spleen (Figure S2A 
in Supplementary Material), as well as increased total cell numbers 
(data not shown) in mice treated either with IL2c alone or in com-
bination with Rapa or MR1. This was mainly due to an increase 
in the frequency of CD4+Foxp3+ T  cells, with proportionally 
decreased frequencies of CD8+ T cells in the LN and spleen (Figure 
S2B–I in Supplementary Material). Therefore, therapies combin-
ing IL2c with Rapa or MR1 allowed preferential expansion of 
Treg in vivo.
Thus, we hypothesized that Rapa or MR1 given in combina-
tion with IL2c at the time of Tx may control the alloreactive 
T-cell pool and proportionally increase Treg. The graft survival 
curves presented in Figure 3A clearly demonstrate that IL2c in 
combination with CD154–CD40 co-stimulation blockade, but 
not with Rapa, could promote tolerance to MHC class I-and 
II-mismatched skin grafts [MST >  100, 18, and 14  days; in 
IL2c + MR1, IL2c + Rapa, and control non-treated (Ntt) groups, 
respectively] in immunocompetent recipients. Allografts from 
tolerant mice were macroscopically healthy at day 100 with no 
retraction or necrosis and displayed hair growth. To determine 
the mechanisms leading to the induction and maintenance of 
tolerance, we analyzed and compared alloreactive T-cell 
responses in the dLN (Figure 3) and spleen (data not shown) of 
control and IL2c + MR1-treated mice at day 7 as well as day 100 
after Tx. Early after Tx, the presence of an immunomodulatory 
drug allowed slight reduction of the frequency of alloreactive 
CD4+ T cells, with an increase in the proportion of Foxp3+ cells 
(40 and 23%, in IL2c + MR1 and control groups, respectively) 
(Figures 3B,C). There was in addition a marked decrease in 
the population of activated CD4+ and CD8+ T cells, as well as of 
CD4+IFN-γ+, CD8+IFN-γ+, and CD4+IL-2+ Teff together with 
increased frequencies of CD4+IL-10+ T cells (Figures 3D–H). 
Even at the late time-point of 100 days, IL2c + MR1-treated 
tolerant mice displayed an immunoregulatory phenotype 
with sustained higher frequencies of CD4+Foxp3+ T cells and 
CD4+IL-10+ T cells compared to control non-treated mice that 
rejected their allografts after Tx (Figures 3I,J). IL2c + MR1 also 
promoted maintained significant reduction in CD4+IFN-γ+ 
and CD4+IL-2+ Teff (Figures 3K,L). Hence, the expansion of 
Treg at the time of Tx in combination with short-term CD154–
CD40 co-stimulation blockade shifted the alloreactive T-cell 
pool toward regulation, favoring Tx tolerance.
The combination of il2c and anti-cD154 
efficiently regulates Donor-specific 
cellular and humoral alloimmune 
responses
Next, we analyzed the homing properties of the Treg expanded 
in vivo at the time of an allogeneic Tx. On day 7, the histological 
integrity of grafted skins was preserved in IL2c + MR1-treated 
mice (Figure  4A) in contrast to control grafts that showed 
marked lymphocytic infiltration and tissue destruction. A 
greater number of Foxp3+ cells could be identified in the grafted 
skins of IL2c +  MR1-treated mice by immunohistochemistry 
(Figure  4B), as also confirmed by flow cytometry analysis of 
FigUre 2 | il2c-expanded Treg prolong Mhc-mismatched skin grafts survival in non-lymphopenic mice. B6 mice were treated with IL2c or drugs and 
underwent B6D2 skin grafts. (a) Graft survival. Mice were sacrificed at rejection to analyze the spleen and graft draining lymph nodes (LN) (not shown for spleen). 
(B) Total cell counts in the graft draining LN. Frequency and numbers of (c) CD4+; (D) CD8+; (e) CD4+Foxp3+; and (F) CD4+CD25+ T cells. (g,h) MFI of CD44 and 
CD62L expression on CD4+ and CD8+ T cells. Frequency of (i) B220+ B cells; (J) IFN-γ+ CD4+; and CD8+ T cells; (K–M) IL-2+, IL-10+, and IL-17+ CD4+ T cells. MFI, 
mean fluorescence intensity; MST, median survival time. n = 5–8 mice/group (*P < 0.05, **P < 0.01, and ***P < 0.001).
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digested grafts showing a significant twofold increase in Foxp3+ 
cells in comparison to control mice (Figure  4C). These results 
indicated that expanded Treg migrated to the allograft to prevent 
tissue damage by alloreactive Teff.
The importance of antigen specificity in the effectiveness of 
Treg function in the setting of SOT has been previously dem-
onstrated (5, 25, 26). Therefore, we investigated whether Treg 
expanded directly in vivo at the time of antigen exposure would 
FigUre 3 | The combination of il2c with Mr1, but not rapamycin (rapa), promotes tolerance to Mhc-mismatched skin grafts in immunocompetent mice. 
B6 mice received IL2c with MR1, Rapa, or were left untreated (Ntt), and underwent B6D2 skin grafts. (a) Graft survival. Mice from control Ntt and IL2c + MR1 groups were 
sacrificed on day 7 to monitor early immune effectors in the graft draining lymph nodes. Frequency of (B) CD4+ and CD8+, (c) CD4+Foxp3+ T cells. (D) CD44 expression on 
CD4+ and CD8+ T cells. Frequency of (e–h) CD4+IFN-γ+, CD8+IFN-γ+, CD4+IL-2+, and CD4+IL-10+ T cells. Frequency of (i) CD4+Foxp3+ T cells; (J–l) IL-10+, IFN-γ+ and 
IL-2+ CD4+ T cells; in rejecting (day 14) and tolerant mice (day 100). MST, median survival time. n = 3–5 mice/group (*P < 0.05, **P < 0.01, and ***P < 0.001).
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FigUre 4 | il2c in combination with Mr1 regulates donor-specific alloimmune responses. (a–c) Skin grafts from control non-treated (Ntt) and 
IL2c + MR1-treated tolerant mice were analyzed at day 7. (a) H&E staining. (B) Foxp3 immuno-staining. (c) Frequency of CD4+Foxp3+ T cells. (D) Frequency of 
I-Ab H-Y tetramer+ CD4+Foxp3+ T cells in lymph nodes and spleen from PBS- or IL2c-treated female B6 mice, immunized with male B6 dendritic cells (DC). (e) In 
vitro rechallenge assay. CD25− and CD25+ CD4+ T-cell subsets were isolated from IL2c-treated B6 mice at day 21 after immunization with 5 × 105 BALB/c DC and 
cocultured at different ratios in the presence of allogeneic or third party CBA DC, or polyclonal stimulation. (F) Presence of donor-specific IgG antibodies in the 
serum of non-transplanted, graft rejected (IL2c + rapamycin), or tolerant (IL2c + MR1) mice. Donor (B6D2), syngeneic (B6), or third party (CBA) strains thymocytes 
were used. Representative histology and flow cytometry stainings are shown from one out of 3–4 mice/group. All in vitro cultures were done in triplicates and are 
representative of two independent experiments. Bar graphs indicate mean ± SEM (*P < 0.05, **P < 0.01, and ***P < 0.001).
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gain antigen-specificity. Female B6 mice were injected subcuta-
neously (s.cut) with male B6 DC on day 1 of IL2c treatment. On 
day 21 post immunization, male antigen-specific CD4+ T cells 
were detected in secondary lymphoid organs using a MHC 
class II tetramer specific for the immunodominant minor DbY-
encoded H-Y antigen. As compared to PBS-treated immunized 
mice, IL2c treatment allowed expansion of CD4+Foxp3+ Treg 
with enrichment of the H-Y+ fraction (Figure 4D), preferentially 
at the injection site dLN. To determine whether IL2c-expanded 
Treg could suppress alloreactive T  cells in an antigen-specific 
manner, B6 mice were immunized with BALB/c DC on day 1 
of IL2c treatment. CD4+CD25+ and CD4+CD25− T  cells were 
selected from these mice to perform an in  vitro suppression 
assay in the presence of DC from either BALB/c or third-party 
CBA mice. Treg expanded in the presence of BALB/c DC were 
significantly more efficient at suppressing the proliferation of 
Tconv stimulated with BALB/c in comparison to CBA DC or 
polyclonally (Figure 4E). Altogether, these data suggested that 
the expansion of Treg in the presence of donor antigens allowed 
enriching the pool in antigen-specific Treg, thus increasing 
their suppressive capacity specifically toward donor antigens 
compared to polyclonal natural Treg.
Donor-specific alloantibodies (DSA) have been implicated in 
promoting both acute and chronic rejection (27, 28). We moni-
tored the appearance of DSA in control and treated mice by flow 
cytometry (29) and observed significant lower MFIs of IgG in 
the sera of tolerant IL2c + MR1-treated compared to rejecting 
IL2c + Rapa-treated mice (Figure 4F). Control serum from non-
grafted mice and recipient serum incubated with syngeneic B6 or 
third-party CBA thymocytes had background levels of IgG. This 
indicated that IL2c + MR1 therapy controlled alloreactive B-cell 
activation and the production of alloantibodies, contributing to 
long-term graft acceptance. As tolerance was not achieved with 
IL2c alone or combined with Rapa, these results suggested that 
the CD154–CD40 pathway plays an important role in antibody-
mediated chronic rejection.
cD28-B7 co-stimulation Blockade allows 
In Vivo expansion of Treg, without 
Promoting allograft Tolerance
Next, we investigated whether blocking the CD28-B7 co-stim-
ulation pathway using CTLA-4 Ig, a fusion protein currently 
used as maintenance therapy in kidney transplant recipients, in 
combination with IL2c would also promote allograft survival 
in our model. CTLA-4 Ig also allowed significant expansion 
of Treg in vivo, similar to IL2c + Rapa or IL2c + MR1 treat-
ment. Indeed, increased frequencies of CD4+Foxp3+ Treg were 
present in the enlarged LN and spleen of mice treated with IL2c 
in combination with CTLA-4 Ig, with proportionally decreased 
frequencies of CD8+ T  cells (Figure S2 in Supplementary 
Material).
When B6 mice were grafted with B6D2 donor skins, treat-
ment with either CTLA-4 Ig alone or IL2c + CTLA-4 Ig mar-
ginally prolonged allograft survival (MST =  15 and 17  days, 
respectively) (Figure 5A). Alloreactive T- and B-cell responses 
of IL2c + CTLA-4 Ig-treated recipients were compared to that 
of IL2c + MR1-treated mice at the same time-point (day 7 post 
Tx). Although the addition of CTLA-4 Ig allowed to some extent 
the expansion of Treg and controlled the activation of CD4+ and 
CD8+ T cells and IFN-γ production when compared to controls, 
it was not as effective as IL2c +  MR1 in particular regarding 
CD8+ T-cell activation and effector function (Figures  5B–H). 
Furthermore, IL2c +  CTLA-4 Ig could not efficiently prevent 
alloantibody production (Figure  5I). Taken together, these 
findings supported that in combination with IL2c, targeting the 
CD28–B7 pathway was insufficient to dampen the alloresponse 
across MHC barriers in non-lymphopenic recipients, in particu-
lar due to inadequate control of CD8+ Teff and the production 
of DSA.
Treg Function in response to alloantigens 
is Better Preserved under cD154–cD40 
Blockade
The competitive interaction of CTLA-4 constitutively expressed 
on Treg with B7.1/2 ligands is one mechanism used by Treg 
to regulate APC and promote the production of indoleamine 
2,3-dioxygenase (IDO), a potent immunoregulatory molecule 
(30). Therefore, we investigated whether CTLA-4 Ig may inter-
fere with Treg-mediated immune regulation in our setting. 
CD4+ T-cell subsets were purified from non-manipulated B6 
mice and CD4+CD25+ Treg were cocultured with CFSE-labeled 
CD4+CD25− Tconv for 6 days, in the presence of allogeneic B6D2 
DC and either MR1 or CTLA-4 Ig. In a primary MLR, blocking 
either the CD154–CD40 or CD28–B7 pathway had no effect 
on Tconv or on the suppressive capacity of Treg (Figure  6A). 
However, as compared to CTLA-4 Ig, the addition of MR1 in the 
CD25−:CD25+ cocultures resulted in slightly more efficacious 
inhibition of CD4+IFN-γ+ Teff and allowed significant induction 
and expansion of CD4+Foxp3+ Treg in the presence of allogeneic 
DC (Figures 6B,C).
We further evaluated the potential of combining IL2c with 
either MR1 or CTLA-4 Ig in dampening antigen-specific Teff 
responses upon rechallenge. B6 mice were immunized with 
B6D2 DC while receiving either no treatment (untreated), 
IL2c + MR1, or IL2c + CTLA-4 Ig. Tconv and Treg were isolated 
from the different groups on day 7 and rechallenge MLR were 
performed in the presence of B6D2 DC. Compared to naïve 
Treg (isolated from non-immunized mice, histogram as for 
Figure 6A), in vivo antigen-experienced Treg were more sup-
pressive. Additionally, Treg expanded in the presence of MR1 
or CTLA-4 Ig had enhanced suppressive capacity compared to 
Treg from the untreated group (Figure  6D). As compared to 
Tconv purified from immunized untreated mice, the in  vitro 
proliferation of Tconv was not modified by any previous in vivo 
drug exposure; however, in  vivo exposure to both MR1 and 
CTLA-4 Ig significantly diminished the frequency of allospe-
cific CD4+IFN-γ+ Teff. Moreover, in cocultures only previous 
exposure to MR1 further increased suppression by in  vivo-
expanded Treg (Figure 6E). Thus, in the setting of an allospecific 
recall response, treatment with MR1 not only enhanced Treg 
suppressive capacity but also prevented antigen-specific Teff 
differentiation.
FigUre 5 | effect of cTla-4 ig co-stimulation blockade on il2c-mediated Treg expansion and skin allograft survival. B6 mice received no treatment 
(Ntt), CTLA-4 Ig alone, or in combination with IL2c and underwent B6D2 skin grafts. Mice were sacrificed at rejection to analyze graft draining lymph nodes cells in 
comparison to tolerant IL2c + MR1-treated mice, at a similar time-point after transplantation. (a) Skin graft survival. Frequency of (B) CD4+; (c) CD8+, and  
(D) CD4+Foxp3+ T cells. (e,F) Mean fluorescence intensity (MFI) of CD44 expression on CD4+ and CD8+ T cells, respectively. (g,h) Frequency of IFN-γ+ CD4+ and 
CD8+ T cells, respectively. (i) Detection of donor-specific IgG antibodies in the serum of IL2c + CTLA-4 Ig and IL2c + MR1-treated mice. n = 3–8 mice/group 
(*P < 0.05, **P < 0.01, and ***P < 0.001).
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il2c combined with anti-cD154 Prolongs 
allograft survival in the Presence of 
Preexisting Memory T cells
Alloantigen-specific T- and B-cell sensitization prior to Tx as 
well as the presence of cross-reactive memory T cells (Tm) have 
been associated with increased risks of acute and chronic rejec-
tion as well as hurdles for tolerance induction (31, 32). Thus, to 
investigate the clinical relevance of our proposed therapy, we 
investigated the potential of IL2c + MR1 to promote Tx tolerance 
in the presence of preexisting donor-specific and cross-reactive 
memory. B6 mice were either immunized with donor strain DC 
(alloreactive memory) or with anti-CD3 (cross-reactive memory) 
before receiving a B6D2 skin graft (Figure  7A). As in naive 
recipients and using a similar experimental setting, we could 
demonstrate that IL2c + MR1 therapy allowed selective expan-
sion of antigen-specific CD4+Foxp3+HY+ Treg in the presence of 
Tm in sensitized mice (data not shown). Taking this finding into 
account, we hypothesized that IL2c + MR1 given at the time of 
Tx may still prove efficacious in sensitized mice. In comparison to 
untreated sensitized recipients that experienced accelerated rejec-
tion upon re-exposure to a second graft (MST = 7 and 10 days; in 
alloreactive and cross-reactive groups, respectively), IL2c + MR1 
treatment allowed prolonged graft survival in the presence of both 
preexisting donor-specific and cross-reactive Tm (MST = 15 and 
19 days, respectively) (Figure 7B). However, the presence of Tm 
before Tx abrogated the induction of tolerance compared to mice 
with a predominantly naïve immune repertoire.
The addition of anti-lFa-1 Treatment 
enhances allograft survival in sensitized 
Mice
The integrin leukocyte function-associated antigen-1 (LFA-
1, CD11a) was shown to be upregulated on Tm and to play 
a crucial role in the trafficking of these cells to the site of 
antigenic challenge (33). The addition of anti-LFA-1 to the 
IL2c + MR1 combination therapy significantly enhanced graft 
survival in the presence of both preexisting donor-specific 
and cross-reactive Tm (MST = 40 and 41 days; in alloreactive 
FigUre 6 | suppressive function of il2c-expanded Treg in the presence of co-stimulation blockade. (a–c) CD4+CD25− (CD25−) and CD4+CD25+ (CD25+) 
T cells were isolated from naïve B6 mice. CFSE-labeled CD25− cells (1 × 105) were cultured alone or 1:1 with unlabeled CD25+ in the presence of 0.2 × 105 
allogeneic B6D2 dendritic cells (DC) and various drugs for 6 days. (D,e) B6 mice were immunized with 5 × 105 allogeneic B6D2 DC and either left untreated or 
received IL2c + MR1 or IL2c + CTLA-4 Ig. On day 7 after immunization, CD4+ T-cell subsets were isolated from pooled lymphoid organs and the CFSE-labeled 
CD25− subset was cocultured with CD25+ and B6D2 DC for 6 days before assessment by flow cytometry. (a,D) CFSE dilutions. (B,e) Frequency of IFN-γ+CD4+ 
proliferating T cells. (c) Foxp3 expression by CD4+ proliferating T cells. All in vitro conditions were plated in triplicates and data are shown from one out of two 
representative experiments. Bar graphs indicate mean ± SEM (***P < 0.001).
11
Govender et al. In Vivo Treg Expansion and Allograft Tolerance
Frontiers in Immunology | www.frontiersin.org April 2017 | Volume 8 | Article 421
FigUre 7 | il2c in combination with Mr1 prolongs Mhc-mismatched skin graft survival in the presence of preexisting memory T cells, and this 
effect is enhanced by anti-lFa-1 treatment. (a) Recipient B6 mice were immunized with either 5 × 105 B6D2 mature dendritic cells (DC) (circles) or 0.5 mg/kg 
anti-CD3 (squares), followed 8–10 weeks later by a B6D2 skin graft. Mice were left untreated (Ntt) or received IL2c + MR1, with or without anti-LFA-1 (black and 
gray symbols, respectively). (B) Graft survival. (c–F) Phenotype and effector function of T cells in the draining lymph nodes at rejection. Frequency of (c) 
CD4+Foxp3+; (D) CD4+IL-10+; (e) CD4+IFN-γ+, and (F) CD8+IFN-γ+ T cells. n = 4–6 mice/group (*P < 0.05, **P < 0.01, and ***P < 0.001).
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and cross-reactive groups, respectively) (Figure  7B). The 
prolonged graft survival in anti-LFA-1-treated mice could 
not be attributed to augmented immunoregulatory responses 
as there was no difference in the frequency of CD4+Foxp3+ 
and CD4+IL-10+ T  cells in the graft dLN compared to mice 
that received IL2c  +  MR1 with no addition of anti-LFA-1 
(Figures 7C,D). However, we observed significant decreased 
IFN-γ production by CD4+ and CD8+ T cells in anti-LFA-1-
treated mice (Figures 7E,F).
To further analyze the added effect of anti-LFA-1 treatment, 
we compared the kinetics of T-cell activation within experimental 
groups by monitoring the expression of the activation/memory 
marker CD44 and of CD62L on peripheral blood T cells at different 
time-points (8–10 weeks after immunization but prior to Tx, day 
7 after Tx, and at rejection). Donor DC pre-sensitized and anti-
CD3 pretreated mice that received anti-LFA-1 at the time of Tx, 
had significantly decreased CD44 and increased CD62L expres-
sion on both CD4+ and CD8+ T cells on day 7 (Figures 8A–D), 
indicating that the addition of anti-LFA-1 treatment contributed 
to controlling the activation and homing potential of circulating 
alloreactive T cells, therefore further prolonging graft survival in 
combination with IL2c + MR1.
FigUre 8 | in pre-sensitized mice, addition of anti-lFa-1 to il2c-Mr1 therapy restricts the activation and effector function of alloreactive T cells in 
response to an allograft. B6 mice were tail-bled at day 0, 10 weeks post immunization (with B6D2 DC or anti-CD3), which corresponded to the day of 
transplantation and at day 7 post B6D2 allograft for flow cytometry analysis. (a–D) Changes in mean fluorescence intensity of CD44 and CD62L expression on 
peripheral CD4+ and CD8+ T cells. n = 4–6 mice/group (*P < 0.05, **P < 0.01, and ***P < 0.001).
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Donor-specific B-cell responses Mediate 
late rejection in Pre-sensitized Mice 
despite the addition of anti-lFa-1
Recipients that received IL2c + MR1 in combination with anti-
LFA-1 eventually underwent late graft rejection, even though 
immunoregulatory T cells were present and Teff allo responses 
were dampened. Hence, we analyzed the role of B cells in medi-
ating late rejection in pre-sensitized recipients harboring either 
donor-specific or cross-reactive memory cells. When analyzing 
dLN of transplanted mice at rejection, we observed no difference 
in the frequency of B220+ B cells in the dLN of non-immunized 
compared to sensitized recipients that received IL2c + MR1 alone 
or with anti-LFA-1 (Figure  9A). However, as measured at the 
time of graft rejection, treatment with either IL2c + MR1 alone 
or in combination with anti-LFA-1 did not control the elevated 
levels of DSA in the serum resulting from sensitization prior to 
Tx (Figure  9B). We subsequently analyzed the phenotype of 
B cells present in graft dLN at rejection and observed that neither 
IL2c + MR1 therapy nor the addition of anti-LFA-1 could control 
the upregulation of the co-stimulatory molecule CD80 on B cells 
in pre-sensitized transplanted mice (Figure 9C). Furthermore, in- 
dependent of the IS treatment, graft dLN B cells had persistent 
increased expression of MHC class II, which could indicate their in- 
creased antigen-presenting potential (Figure  9D). These data 
suggested that, as opposed to the observed regulation of Teff, 
IL2c + MR1 + anti-LFA-1 therapy had no effect on donor-specific 
B-cell responses that mediated late rejection in pre-sensitized 
mice.
DiscUssiOn
In recent years, Treg-based immunotherapy has emerged as a 
promising strategy to promote operational tolerance after SOT. 
The possibility to expand in vivo Treg using IL-2 would allevi-
ate some hurdles associated with cumbersome and costly 
in vitro procedures, including Treg production in GMP facilities 
(12, 13, 34, 35). Here, we investigated whether the use of the 
IL-2/JES6-1 complex (IL2c), designed to specifically expand 
Treg, would allow the induction of Tx tolerance across MHC 
barriers, in non-lymphopenic recipients of highly immunogenic 
skin allografts. We observed that IL2c given at the time of Tx 
expanded donor-specific Treg that delayed graft rejection, in 
FigUre 9 | in pre-sensitized mice, addition of anti-lFa-1 to il2c-Mr1 therapy has no effect on B-cell mediated graft rejection. B6 mice were 
immunized [with B6D2 dendritic cells (DC) or anti-CD3] 10 weeks prior to a B6D2 skin graft. All transplanted mice received IL2c-MR1 therapy, without or with 
anti-LFA-1. At rejection, graft draining lymph nodes (LN) and serum were harvested for flow cytometry analysis. (a) Frequency of B220+ B cells in graft draining LN. 
(B) Levels of alloantibodies measured at 10 weeks post immunization and at rejection. Mean fluorescence intensity (MFI) of (c) CD80 and (D) MHC class II 
expression on B220+ B cells in the graft draining LN. n = 4–6 mice/group (*P < 0.05, **P < 0.01, and ***P < 0.001).
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part by regulating alloreactive T  cells activation and effector 
function. However, IL2c alone was not sufficient to induce Tx 
tolerance which is consistent with previous studies highlighting 
the importance of controlling the clonally expanding alloreac-
tive Teff pool to promote Treg-mediated peripheral tolerance 
(9, 10). In a previous study, we had shown that the adoptive trans-
fer of 2 ×  106 donor-specific Treg into non-lymphopenic mice 
1  day before an MHC-mismatched skin Tx resulted in similar 
graft prolongation (MST = 23 days, P < 0.001) as described in 
the current study (5). Thus, in stringent Tx settings, additional 
immunomodulatory therapies are needed even in the presence of 
very high Treg frequencies (>10-fold physiological values) at the 
time of allorecognition. Many experimental models demonstrat-
ing the potential of Treg to induce donor-specific Tx tolerance 
have used lymphopenic mice (7, 8, 25). These models are, how-
ever, often biased in favor of Treg (36). Recently, IL2c treatment 
alone was shown to induce tolerance in immunocompetent 
recipients of MHC-mismatched pancreatic islets (37). However, 
we have reported that the streptozotocin-induced diabetes model 
results in profound transient lymphopenia in peripheral blood 
and secondary lymphoid organs, resulting in a relative increase in 
the Treg pool (38). Indeed, we observed a direct cytotoxic effect of 
streptozotocin, particularly on CD8+ T cells and B cells. Thus, it 
is desirable to perform more studies, using various experimental 
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models and transplanting across different donor-recipient strain 
combinations, before drawing conclusions on the efficacy of Treg-
based immunoregulatory strategies.
The importance of combining Treg-based immunotherapy 
(either via adoptive transfer of high numbers or in vivo expan-
sion) with the right IS drugs to promote allograft survival in non-
lymphopenic hosts was illustrated in our study. Indeed, while we 
observed similar IL-2-mediated Treg expansion in combination 
with Rapa, CTLA-4 Ig, or MR1 (39, 40), only combination with 
CD154–CD40 co-stimulation blockade promoted tolerance 
to MHC-mismatched skin grafts. Our data suggest that in our 
experimental model, while the increased pool of Treg mainly 
allowed the regulation of CD4+ Teff, additional blockade of 
CD40L prevented efficient priming and differentiation of naïve 
CD8+ T  cells (41–43), as well as the activation of alloreactive 
B  cells and the production of DSA. Indeed, CD40 is constitu-
tively expressed on DC and B cells, and its ligation was shown to 
upregulate the expression of co-stimulatory and MHC molecules, 
as well as of the transcription factor Blimp-1 in B cells required 
for the differentiation into plasma cells (44). Thus, the addition 
of MR1 contributed to the maintenance of allograft tolerance by 
preventing B-cell activation and the production of deleterious 
de novo DSA (28) as well as possibly limiting chronic indirect 
pathway activation, which are all important mediators of chronic 
rejection (45, 46). We also hypothesized that, as compared to 
CTLA-4 Ig, the effect of MR1 would be even greater in sensitized 
hosts, as Tm and in particular CD8+ Tm were shown to be less 
dependent on CD28-mediated co-stimulation. Moreover, the 
administration of CTLA-4 Ig (rather than a CD28 antagonist) 
may have interfered with the regulatory crosstalk between Treg 
and APC (47). Finally, although Rapa has been shown to promote 
Treg survival and reduce alloreactive Teff (48–50), it did not 
further enhance graft survival when combined with IL2c in our 
experimental setting.
As supported by flow cytometry phenotypic analysis and 
in  vitro suppressive assays, we confirmed that IL2c therapy 
expanded a subset of Treg and, corroborating recent data, the 
combination with CD154–CD40 co-stimulation blockade 
did not hinder their proliferation or suppressive function 
(51–53). Based on the expression of Helios, we assumed that 
the expanded Treg collected in the peripheral blood and lym-
phoid organs were mainly thymic-derived (23). In the light of 
current data, this implies that IL2c-expanded Treg would be 
more stable in their Foxp3 expression than peripheral-induced 
Treg. IL2c treatment did not induce significant expansion of 
CD8+Foxp3+ regulatory cells, a subset of potent suppressor cells 
which has been recently described (Figure S1 in Supplementary 
Material) (54). Importantly, the expansion of Treg at the time 
of allorecognition allowed enrichment of donor-specific Treg. 
Indeed, in the setting of SOT, the efficacy, and superiority 
(as compared to polyclonal Treg) of donor-specific Treg to induce 
and maintain tolerance has been highlighted in several studies (5, 
7, 25, 55). Antigen-specificity also contributed to specific homing 
of Treg in the graft dLN and into the grafted tissue to dampen 
allospecific Teff responses, thus protecting the allograft.
The presence of preexisting donor-reactive memory cells 
is rarely represented in experimental rodent models of SOT, 
where the starting pool of T and B  cells is almost exclusively 
naïve, making the induction of tolerance potentially easier to 
achieve. Therefore, we tested the robustness of IL2c combined 
with CD154–CD40 co-stimulation blockade to promote MHC-
mismatched graft survival in pre-sensitized non-lymphopenic 
hosts. Our data demonstrated that, as in non-immunized mice, 
IL2c + MR1 given at the time of Tx allowed the selective in vivo 
expansion of Treg and the induction of IL-10+ immunoregulatory 
CD4+ T cells, as well as, to some extent, the control of alloreactive 
Teff. The addition of anti-LFA-1 further dampened the activa-
tion and effector function of alloreactive Teff, hence leading to 
significant prolonged graft survival. Similarly, in an experimental 
heart Tx model, anti-LFA-1 treatment inhibited early infiltration 
of preexisting host CD8+ Tm into allografts, leading to prolonged 
survival (56). In the clinic, anti-LFA-1 (Efalizumab)-based main-
tenance regimens were shown to promote insulin-independence 
in type 1 diabetic recipients of pancreatic islets allografts (57, 
58). In our experimental setting, while the T-cell alloreactive 
compartment was controlled by this enhanced combination 
therapy, late graft loss occurred mainly due to insufficient control 
of B-cell-mediated alloresponses. Although anti-LFA-1 treat-
ment has been shown to prevent the migration of naïve B cells 
to T-cell zones within follicular regions of lymphoid organs (59), 
either it was inefficacious in the presence of preexisting antigen-
experienced B cells or possibly supplementary doses should have 
been administered in our model to prevent de novo activation 
of alloreactive B cells. Moreover, as late rather than early acute 
rejection occurred in sensitized mice, the antigen-presenting 
capacity of B cells maintaining chronic indirect pathway T-cell 
alloresponses, rather than alloantibodies, could also be incrimi-
nated in our model and this deserves further investigation (46). 
Finally, our data also highlight the limited potential of Treg per se 
in regulating B-cell activation after SOT, a finding that may be 
relevant to translate therapeutic strategies to the clinical setting.
Overall, our data contribute to a better understanding of the 
complexity of the alloresponse and could help to define new 
immunomodulatory strategies with a potential to be relevant in 
the clinic. Although the use of Treg therapy has appeared very 
promising based on previous experimental data, Treg do not 
appear to have sufficient potency as a stand-alone therapy in the 
setting of clinical SOT. Hence, the challenge will be to design an 
optimized short-term immunomodulatory therapy that could 
promote Treg homeostasis while targeting the alloreactive naïve 
and memory T- and B-cell compartments. Based on the present 
data, we propose to combine the expansion of the donor-specific 
Treg pool at the time of Tx, together with CD154–CD40 blockade, 
at least in non-sensitized hosts.
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